NCT03989882

Brief Summary

The objective of this pilot study is to determine the effects of wheat germ (WG) supplementation on gut health and subsequent effects on markers of inflammation and insulin resistance in overweight individuals. WG is a by-product of wheat processing and an excellent source of omega-3 fatty acids, vitamin E, and fiber. A few studies have shown the health benefits of WG including gut modulatory potential, but the prebiotic functions of WG in humans remain in question and warrant further investigation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 22, 2019

Completed
6 days until next milestone

Study Start

First participant enrolled

May 28, 2019

Completed
21 days until next milestone

First Posted

Study publicly available on registry

June 18, 2019

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2021

Completed
Last Updated

December 7, 2021

Status Verified

December 1, 2021

Enrollment Period

2.5 years

First QC Date

May 22, 2019

Last Update Submit

December 6, 2021

Conditions

Keywords

wheat germoverweightgut microbiomeinflammationinsulin resistance

Outcome Measures

Primary Outcomes (4)

  • Fecal bacteria population

    analyzed by 16sRNA sequencing

    Change from baseline fecal bacteria at 30 days

  • Fecal immunoglobulin A

    analyzed by enzyme-linked immunoassay

    Change from baseline fecal immunoglobulin A at 30 days

  • Fecal zonulin

    analyzed by enzyme-linked immunoassay

    Change from baseline fecal zonulin at 30 days

  • Fecal short chain fatty acids

    analyzed by gas chromatography

    Change from baseline fecal shortchain fatty acids at 30 days

Secondary Outcomes (4)

  • Blood glucose

    Change from baselineblood glucose at 30 days

  • blood glycated hemoglobin

    Change from baseline blood glycated hemoglobin at 30 days

  • blood high sensitivity C-reactive protein

    Change from baseline blood high sensitivity C-reactive protein at 30 days

  • blood insulin level

    Change from baselineblood insulin level at 30 days

Study Arms (2)

Wheat germ

EXPERIMENTAL

Wheat germ energy balls containing 30 g of wheat germ, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.

Other: Wheat germ energy ball

Control

PLACEBO COMPARATOR

Control energy ball containing 30 g of cornmeal, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.

Other: Control

Interventions

wheat germ mixed other ingredients to make an energy ball

Wheat germ
ControlOTHER

corresponding control without wheat germ

Control

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy overweight (body mass index, BMI, between 25.0 - 30 kg/m2) 18-45 years old

You may not qualify if:

  • diagnosed diabetes, heart disease, and cancer tobacco use excessive alcohol use taking mega-doses of antioxidant/vitamin supplements or medications that could interfere with study endpoints such as antibiotics, anti-inflammatory, and glucose-lowering medications major surgery occurring within 6 months pregnant or lactating previous high intake of wheat germ or sensitivity to gluten and wheat products.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nutritional Sciences Department, Oklahoma State University

Stillwater, Oklahoma, 74078, United States

Location

MeSH Terms

Conditions

OverweightInsulin ResistanceInflammation

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesPathologic Processes

Study Officials

  • Edralin Lucas, PhD

    Okklahoma State University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Participants will not know their treatment assignment and energy balls will be in an opaque container.
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 22, 2019

First Posted

June 18, 2019

Study Start

May 28, 2019

Primary Completion

November 30, 2021

Study Completion

November 30, 2021

Last Updated

December 7, 2021

Record last verified: 2021-12

Data Sharing

IPD Sharing
Will not share

Locations